NCT03401528View on ClinicalTrials.gov

A Phase 1 AVB-S6-500 Safety and Tolerability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

June 20, 2018

Study Completion Date

July 31, 2018

Conditions
Healthy Volunteer
Interventions
DRUG

AVB-S6-500

AVB-S6-500 is an investigational drug.

OTHER

Placebo

Matching placebo

Trial Locations (1)

32809

Orlando Clinical Research Center, Orlando

All Listed Sponsors
lead

Aravive, Inc.

INDUSTRY

NCT03401528 - A Phase 1 AVB-S6-500 Safety and Tolerability Study | Biotech Hunter | Biotech Hunter